Needham Cuts Price Target to $185, Expects Double-Digit Growth for Ingrezza
Neurocrine Biosciences reported Q4 revenue of $805.5 million, surpassing the $789.3 million consensus estimate and highlighting its robust commercial portfolio. Needham lowered its price target to $185 from $187 while maintaining a Buy rating and forecasting double-digit Ingrezza growth and 2026 expansion for Crenessity.
1. Q4 Financial Performance
Neurocrine Biosciences delivered fourth-quarter revenue of $805.5 million versus the $789.3 million consensus, driven by strong Ingrezza sales and a diversified commercial portfolio. Management highlighted that these results underscore the company’s ability to sustain growth across multiple neuropsychiatric therapies.
2. Analyst Price Target Adjustment
Needham reduced its Neurocrine price target from $187 to $185 while affirming a Buy rating, citing confidence in Crenessity’s 2026 launch potential and forecasting robust double-digit Ingrezza growth in line with the $2.72 billion consensus.
3. Late-Stage Pipeline Development
The company’s pipeline features two active Phase 3 programs—osavampator for major depressive disorder and direclidine for schizophrenia—positioning Neurocrine to introduce a new medication approximately every two years if trials succeed.
4. Strategic Growth and Diversification
Leadership emphasized diversification beyond Ingrezza, targeting long-term value through late-stage initiatives and steady expansion of its commercial base across neuropsychiatric diseases, reinforcing its position as a neuroscience-focused biopharmaceutical firm.